clinical 1,935 words KG: Purinergic Receptor Targeted Trials in Parkinson's Disease
kind:clinical-trialsection:clinical-trialstopic:parkinsonsstate:published
Contents

Purinergic Receptor Targeted Trials in Parkinson's Disease

Knowledge Graph

Related Hypotheses (12)

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.58
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
Purinergic Signaling Polarization Control
Score: 0.55

Related Analyses (21)

Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed

Related Experiments (30)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40

Knowledge Graph (1 edges)

Purinergic Receptor Targeted Trials in Parkinson's Disease references NLRP3